title: Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion.
abstract: OBJECTIVE
  To retrospectively evaluate the re-injection interval, efficacy and safety of dexamethasone (DEX) intravitreal implant 0.7 mg in the treatment of macular oedema (ME) due to retinal vein occlusion (RVO) in Germany in 2009-2012.
  
  
  METHODS
  Retrospective, multicentre, anonymised observational study of data collected from the first DEX implant 0.7 mg injection through 3-6 months following the last injection. Data were included if the patient was >18 years old, had a diagnosis of ME secondary to branch or central RVO, and received at least 2 DEX implant 0.7 mg injections during routine practice.
  
  
  RESULTS
  Data from 87 patients were analysed. Mean time to re-injection between first and second treatments was 5.03 months in the total RVO population, and 5.46 and 4.52 months for the branch and central RVO subpopulations, respectively. An intraocular pressure increase of >25 mm Hg was recorded in 20% of patients, and 34% of patients began treatment with anti-glaucoma medication, but surgery was not needed for this condition.
  
  
  CONCLUSIONS
  DEX implant 0.7 mg was found to be well tolerated and effective with repeat treatments in clinical practice.
authors.affiliation: Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Augustin
authors.forename: Frank G
authors.initials: FG
authors.lastname: Holz
authors.forename: Christos
authors.initials: C
authors.lastname: Haritoglou
authors.forename: Wolfgang J
authors.initials: WJ
authors.lastname: Mayer
authors.forename: Silvia
authors.initials: S
authors.lastname: Bopp
authors.forename: Alexander F
authors.initials: AF
authors.lastname: Scheuerle
authors.forename: Matthias
authors.initials: M
authors.lastname: Maier
authors.forename: Walter
authors.initials: W
authors.lastname: Sekundo
authors.forename: Dirk
authors.initials: D
authors.lastname: Sandner
authors.forename: Andrew
authors.initials: A
authors.lastname: Shirlaw
authors.forename: Lars-Olof
authors.initials: LO
authors.lastname: Hattenbach
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications*; D019233:Retreatment; D012189:Retrospective Studies; D014792:Visual Acuity / Q000502:physiology
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone